Extending the functional integrity of renal allografts is the primary goal of transplant medicine. The development of donor-specific antibodies (DSAs) posttransplantation leads to chronic active antibodymediated rejection (cAMR) and transplant glomerulopathy (TG), resulting in the majority of graft losses that occur in the United States. This reduces the quality and length of life for patients and increases cost. There are no approved treatments for cAMR. Evidence suggests the proinflammatory cytokine interleukin 6 (IL-6) may play an important role in DSA generation and cAMR. We identified 36 renal transplant patients with cAMR plus DSAs and TG who failed standard of care treatment with IVIg plus rituximab with or without plasma exchange. Patients were offered rescue therapy with the anti-IL-6 receptor monoclonal tocilizumab with monthly infusions and monitored for DSAs and long-term outcomes. Tocilizumab-treated patients demonstrated graft survival and patient survival rates of 80% and 91% at 6 years, respectively. Significant reductions in DSAs and stabilization of renal function were seen at 2 years. No significant adverse events or severe adverse events were seen. Tocilizumab provides good long-term outcomes for patients with cAMR and TG, especially compared with historical published treatments. Inhibition of the IL-6-IL-6 receptor pathway may represent a novel approach to stabilize allograft function and extend patient lives.
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Introduction
Antibody-mediated rejection (AMR) is a unique, significant, and often severe form of allograft rejection. Significant advances have occurred in our ability to predict patients who are at risk for AMR and to diagnose AMR (1, 2) . The pathophysiology of AMR suggests a primary role for antibodies, B cells, and plasma cells. As a result, IVIg, rituximab, and/or plasma exchange (plasmapheresis [PLEX] ) has been leveraged for the treatment of acute AMR (3) (4) (5) (6) (7) . Despite the success of these therapies, posttransplantation AMR, chronic active AMR (cAMR), and transplant glomerulopathy (TG) remain significant problems that are often unresponsive to current therapies (4) . Data from the Deterioration in Kidney Allograft Function study show that most graft losses in the current era of immunosuppression have evidence of cAMR with positive C4d staining (2, 8) . It is estimated that 5000 allografts are lost each year in the United States, primarily from cAMR and TG (9) . The current treatment paradigms rely on reduction of antibody levels to prevent AMR. This raises the importance of maintaining immunosuppression and investigating novel methods to prevent and treat AMR/cAMR that directly address the reduction of donor-specific antibodies (DSAs) and antibody-producing cells.
AMR is frequently seen in patients who are receiving inadequate immunosuppression or are noncompliant with antirejection medications and in those who receive HLAincompatible transplants. In addition, TG is a known consequence of persistent DSA positivity, which rapidly dissipates allograft function, resulting in graft failure and return to dialysis with attendant emotional consequences for the patients and financial consequences for the health care system (10) (11) (12) (13) (14) . No current therapy is US Food and Drug Administration (FDA) approved, and patients are often treated with combination therapies that make analysis of efficacy difficult. Thus, there is a large unmet clinical need. To this end, it is imperative that novel therapies to prevent immunologic injury to the microcirculation be developed and studied in patients with cAMR and TG.
IL-6 is a key cytokine that regulates inflammation and the development, maturation, and activation of T cells, B cells, and plasma cells (15) . Excessive IL-6 production has been linked to a number of human diseases characterized by unregulated antibody production and autoimmunity (15, 16) . We have shown that IL-6-IL-6 receptor (IL-6R) interactions are critical for alloantibody generation in an animal model of alloimmunity (17) . Blockade of these interactions with an anti-IL-6R monoclonal results in significant reductions of alloantibodies, antibody production by splenic and bone marrow plasma cells, direct inhibition of plasma cell anti-HLA antibody production, and induction of T regulatory cells (Tregs) with inhibition of T follicular helper cells (Tfh). Thus, IL-6 shapes T cell immunity and is a powerful stimulant for pathogenic IgG production (18, 19) .
Tocilizumab (Actemra â , Roche/Genentech, San Francisco, CA) is the first-in-class humanized monoclonal aimed at the IL-6R. Tocilizumab binds to both soluble and membrane-bound forms of the IL-6R and is approved by the FDA for treatment of rheumatoid arthritis and juvenile idiopathic arthritis. We recently reported on the efficacy of tocilizumab in reducing anti-HLA antibodies and improving transplant rates in highly HLA-sensitized patients who were resistant to other desensitization strategies (NCT: 01594424; FDA IND: 114362). Tocilizumab significantly reduced DSAs and improved transplantation rates. Protocol biopsy specimens at 6 months posttherapy showed no AMR (20) . Based on our experiences, we developed a treatment protocol using tocilizumab as a "rescue" therapy for patients who demonstrated DSAs plus cAMR with or without TG on biopsy. Most patients showed progressive renal dysfunction and had failed treatment with IVIg plus rituximab with or without PLEX.
Patients and Methods

Patients and treatment design
This single-center, open-label case study was developed and conducted at Cedars-Sinai Medical Center. This was not a sponsored trial. Between 2011 and 2016, 36 patients were offered treatment with tocilizumab (8 mg/kg monthly, maximal dose 800 mg for 6-25 months), based on insurance approval. The objectives of this treatment were to provide a "rescue" therapy for patients with DSA plus cAMR with or without TG who had failed standard of care treatment with IVIg plus rituximab with or without PLEX. Baseline immunosuppression consisted of tacrolimus, prednisone, and mycophenolate mofetil. Tacrolimus levels were maintained in the 8-10 ng/dL range for the first 6 months posttransplantation and then 5-7 ng/mL thereafter. Prednisone was tapered to 5 mg/day by 1 month posttransplantation, and mycophenolate mofetil was maintained in doses of 500-1000 mg twice a day depending on the patient's induction therapy and desensitization status. Doses were adjusted for white blood cell, absolute neutrophil count, and liver function. These patients were deemed treatment failures if they failed to show improvements in serum creatinine levels and reductions in DSA levels 3 months after standard of care treatment was completed. Eligible patients were 6-69 years old; all had kidney allograft biopsy specimens with evidence of cAMR and usually TG with DSA positivity. Banff assessments of biopsy findings at time of study entry were also performed. Based on our previous experience with tocilizumab for desensitization, we described the potential risks and benefits of receiving tocilizumab. If patients agreed, we proceeded. Patients treated with tocilizumab were monitored for renal function, adverse and severe adverse events (AEs and SAEs, respectively), graft and patient survival, and DSA levels. Nine patients also underwent repeat biopsies 1 year after tocilizumab treatment to assess the impact of therapy on pathologic features of cAMR and to determine if continuation of therapy was advisable.
Pathologic methods for assessment of biopsy specimens
For each biopsy, tissue was fixed in alcoholic Bouin fixative and paraffin embedded for routine light microscopy (with hematoxylin-eosin, periodic acid-Schiff, Masson's trichrome, and Jones silver methenamine stains of 2-mm-thick sections) and snap-frozen for immunofluorescence studies, including direct immunofluorescence for IgG, IgA, IgM, C3, C1q, albumin, fibrin, and j and k light chains and indirect immunofluorescence for C4d, performed using a monoclonal anti-C4d antibody as previously described (14) . A portion of cortical tissue was also fixed in 3% glutaraldehyde for electron microscopy, and ultrathin sections of plastic-embedded tissue were cut, stained with uranyl acetate and lead citrate, and examined in a JEOL JEM-1010 or 100CX transmission electron microscope (JEOL Ltd., Tokyo, Japan). This examination included recording the maximal number of circumferential basement membrane layers in the most severely involved peritubular capillaries. For each of the 36 biopsy specimens meeting initial entry criteria, the histologic slides were reviewed by a renal pathologist and graded according to Banff 2007 criteria for CMR and Banff 2013 criteria for AMR, the latter with the modification that chronic glomerulopathy (cg) scores were based solely on light microscopy (i.e. cg1a according to Banff 2013 was considered as cg 0) because not all biopsy specimens were examined with electron microscopy. C4d staining results were taken from the biopsy reports, and staining within ptc was defined as diffuse (estimated~50% of ptc), focal (10%-49%), or negative (<10%) (21) .
Study assessment
Before the initiation of tocilizumab, all patients were tested for exposure to tuberculosis using the PPD skin test. After the initiation of therapy, patients continued their standard immunosuppression and were monitored for viral infections (cytomegalovirus, Epstein-Barr virus, and polyoma BK) every 3 months with the use of polymerase chain reaction techniques (6) . Tocilizumab was given in our infusion center with patients being constantly monitored for AEs/SAEs related to infusions. Doses of tocilizumab were given at 8 mg/kg (maximum of 800 mg) over 60 min after premedication with steroid, acetaminophen, and diphenhydramine as previously described (20) . Patients were also monitored for hypogammaglobulinemia (total IgG <600 mg/mL) and, if present, were treated with nonsucrose IVIg infusions monthly (1 g/kg 9 1 then 0.5 g/kg monthly per clinical response). Renal function was assessed monthly and DSAs were assessed every 3 months. Observations were carried out for up to 6 years with final assessments of patient and graft survivals since index biopsy.
Study oversight
To evaluate the potential benefit of tocilizumab on cAMR and TG, we obtained informed consent from all treated patients to analyze and report results. This study was approved by the institutional review board at Cedars-Sinai Medical Center (IRB #40342). The study was designed, conducted, and evaluated solely by the investigators without external funding. Treatment was given in an open-label manner after discussion of the potential benefits and risks with each patient. Data were maintained in a confidential manner. Data safety monitoring was established to review safety concerns and report any AEs/SAEs. The data analysis and manuscript preparation were completed entirely by the investigators.
Statistical analysis
Continuous variables are described with mean and SD values or median and interquartile ranges (IQRs). We compared means and proportions between groups by using Mann-Whitney test and Fisher's exact test.
The kidney survival analysis was performed from the time of diagnosis of cAMR by index biopsy until a maximal follow-up of 6 years. For the two patients who died with functioning grafts, graft survival was censored at the time of death. Kidney allograft survival was plotted by using KaplanMeier curves. We used STATA (version 14, Data Analysis and Statistical Software) and R (version 3.2.1, R Foundation for Statistical Computing) for the descriptive and survival analyses. All the statistical tests were two-sided, and probability values <0.05 were considered significant.
Results
Baseline characteristics of the kidney-allograft recipients A total of 36 patients were included in the main analysis, with baseline characteristics shown in Table 1 . The mean recipient age was 45.9 AE 16.6 years, and most of the recipients were men (n = 19, 52.8%). Seventeen (47.2%) patients were undergoing repeat transplantation. A total of 20 (55.6%) kidneys were from deceased donors, of whom only one was an extended-criteria donor or highKidney Donor Profile Index donor. The mean number of HLA mismatches was 4.07 AE 1.46. Among the 28 patients with available anti-HLA DSA information at the time of transplant, 10 developed de novo DSAs, which likely occurred through inadequate immunosuppression and medication nonadherence. The remaining patients were highly HLA sensitized at transplantation and likely developed rebound DSAs after transplantation. All patients had evidence of significant pathologic injury at initiation of tocilizumab treatment. Twenty-five (69.4%) of the 36 patients had more than two prior AMR episodes and 33 (91.7%) of 36 received more than two rounds of AMR treatment with pulse steroids, IVIg, rituximab, with or without eculizumab and with or without PLEX for treatment-resistant AMR before the initiation of tocilizumab. At the time of cAMR diagnosis, 31 (86.1%) of 36 patients had a demonstrable HLA-DSAs with class II DSAs predominating. Three patients did not demonstrate HLA-DSAs but showed elevated levels of antiangiotensin type 1 receptor antibodies.
The results of the index cAMR biopsies are presented in Figure 1(A) . The biopsy specimens showed high g and ptc scores (mean: 1.67 AE 1.11 and 1.78 AE 0.58, respectively). The mean C4d graft deposition was 1.54 AE 1.50. The biopsy specimens showed a high cg score with a mean of 1.57 AE 1.03 with moderate atrophy fibrosis (mean interstitial fibrosis/tabular atrophy [IF/TA]: 0.93 AE 0.72). Figure 1(B) shows the Banff 13 (14) 
Long-term kidney and patient survival, injury phenotypes, and function
The median follow-up was 3.26 years (IQR 1.82-3.81) with a maximal follow-up of 8 years. Among the 36 recipients treated with tocilizumab, only four had a graft loss (11.1%). Figure 2(A)-(C) shows the Kaplan-Meier assessments of graft and patient survivals. Figure 2(A) shows graft survival for tocilizumab-treated patients during the study period since the initial biopsy. The patients treated with tocilizumab exhibited good allograft survival with a graft survival probability of 80% at 6 years post-cAMR diagnosis. Tocilizumab-treated patients with TG exhibited good allograft survival with a graft survival probability of 77% at 6 years post cAMR ( Figure 2B ). Patient survival is presented in Figure 2 (C). The patient survival was good at 6 years with a survival probability of 91%. Figure 3(A) shows estimated glomerular filtration rates (eGFR) for tocilizumab-treated adult patients (>18 yrs). Initial eGFRs were lower (38.8 mL/min/1.73 m 2 ) when pediatric (<18 yrs old) patients ( Figure 3B) were removed from the cohort. However, eGFRs for both cohorts remained stable during the study period. Figure 4 shows the impact of tocilizumab on immunodominant (iDSA) levels. iDSAs are defined as the strongest DSAs detected in the patients' sera. iDSA values declined significantly beginning at 24 months.
Determinants of kidney allograft loss
A total of four patients had graft loss, which were due to cAMR. All four patients had initiated tocilizumab after receiving more than two rounds of AMR therapy. All four patients had class 2 DQ and DR iDSAs present. Of interest, tocilizumab was discontinued for medical reasons in one patient and for financial reasons in the other three about 6 months before all graft losses were seen. Although it is uncertain, we must consider the possibility that rebound in IL-6-IL-6R signaling after cessation of tocilizumab is responsible for the initiation of alloimune response and allograft loss.
Adverse events
We next assessed AEs associated with tocilizumab administration. Thirteen patients had infectious AEs: a total of five patients had cytomegalovirus infection, two patients had polyoma BK infection that resolved with treatment, and one patient was diagnosed with trichodysplasia spinulosa (a benign skin condition related to polyoma virus) that resolved 1 month after the completion of tocilizumab therapy. Seven patients had bacterial infections, which resolved with treatment, usually without the need for cessation of tocilizumab therapy. All infectious events resolved with directed treatment and without the need to stop tocilizumab therapy. Three patients had cardiovascular complications: one patient had a stroke with no residual deficit (the patient continued tocilizumab therapy but was told to discontinue erythropoietin-stimulating agent) and two patients had non-ST-segment elevation myocardial infarction (NS-TEMI) (one patient had NSTEMI 2 years after tocilizumab therapy and one patient had NSTEMI after the ninth tocilizumab dose, possibly attributed to hyperkalemia in the setting of dehydration and spironolactone). One patient had transient visual disturbance with resolution. Eight patients developed hypogammaglobulinemia defined by IgG <600 mg/dL during tocilizumab therapy. Two deaths were noted in the tocilizumab treatment group: one patient died from diabetic coma 5 months after completion of tocilizumab therapy and another patient died from bacterial pneumonia 9 months after the completion of tocilizumab therapy. Both deaths were thought to be unrelated to treatment.
Discussion
IL-6 is an important mediator of inflammation that is critical to shaping T cell immunity and inhibiting Tregs while increasing T helper 17 cell (Th17) populations (18, 19) . IL-6 is also critical for the progression of na€ ıve B cells to plasmablasts and mature plasma cells. Plasmablasts also produce copious amounts of IL-6 (22) . Excessive IL-6 production has been linked to a number of human diseases characterized by unregulated antibody production and autoimmunity (15, 16) . Reports have shown that tocilizumab also reduces antibody-producing cells, diminishes inflammatory markers, and improves clinical symptomatology in a number of other autoimmune diseases (15, 16, 23, 24) . Recent clinical observations and animal models have shown that IL-6 may be important in mediating allograft rejection. IL-6 production increases in mouse allografts undergoing rejection and is responsible for allogeneic T cell infiltration (25) . In addition, IL-6 deficiency or inhibition with anti-IL-6, in combination with costimulatory pathway blockage by cytotoxic T-lymphocyte-associated protein 4-Ig, induces graft acceptance (26) .
Using a mouse model of chronic allograft damage, Tse et al (27) showed that B cells infiltrating the allograft produced a number of proinflammatory cytokines, including IL-6, that were responsible for the induction of IF/TA. Animals treated with anti-CD20 posttransplantation showed significant reduction in IF/TA scores. Indeed, anti-CD20 treatment is known to eliminate IL-6-producing B cells in patients with multiple sclerosis, which correlates with induction of disease remission (28) .
Data from relevant animal models are also supportive of an important role for IL-6 in the mediation of allograft vasculopathy. Von Rossom et al (29) used a murine aortic interposition model of vascular rejection to examine the mechanism via which IL-6 contributes to the pathogenesis of vascular rejection and transplant arteriosclerosis. The authors conclude that donor-derived IL-6 amplifies and expands allogeneic T cell response that cause vascular rejection.
Fogal et al (30) used a humanized mouse model of arterial allograft rejection to show a critical role for IL-6 produced by endothelial cells as a major factor responsible for intimal proliferation. Neutralization of IL-6 significantly reduced endothelial cell IL-6 production and intimal proliferation. This was thought to be mediated by the emergence of CD161 + CD4 + Tregs (30) .
It is accepted that IL-6 drives CD4 T cells toward Th17 phenotype while negating Treg differentiation (18, 19) . Neutralization of IL-6 reduces allograft rejection by allowing emergence of Tregs (19, 31) . Recent evidence also indicates that IL-6 triggers IL-21 production by Tfh, driving B cell maturation to plasma cells during antibody responses (22, 31) . Anti-IL-6R antibodies have shown significant reduction in graft-versus-host disease and allograft rejection in animal models associated with increased Treg differentiation (25, 32) .Since the introduction of tocilizumab, reports indicate that inhibition of the IL-6-IL-6R pathway may have significant benefits in the prevention and treatment of vasculitic disorders, primarily by reducing antibody-producing cells in treated patients. Recent human data (22) also suggest that IL-6 production by antigen-activated plasmablasts is responsible for Tfh cell development and germinal center formation. Indeed, when patients with active rheumatoid arthritis were examined, circulating Tfh and plasmablast numbers were elevated. Treatment with tocilizumab significantly reduced Tfh cell numbers and IL-21 production by Tfh and circulating plasmablasts. Tocilizumab can also induce significant increases in Tregs in patients with rheumatoid arthritis. This also correlated with responses to therapy (31) . Thus, T cell and B cell hyperreactivity is significantly affected in humans treated with tocilizumab (33).
We recently reported on a trial of tocilizumab for desensitization of HLA-sensitized patients who failed desensitization with IVIg plus rituximab with or without PLEX. This was a phase 1/2 open-label study (NCT01594424) (20) . In this trial, we found tocilizumab improved transplant rates in this difficult to desensitize patient group. DSAs that were resistant to other therapies were significantly reduced with tocilizumab therapy, and none of the transplanted patients showed AMR, cAMR, or TG in 6-month posttransplantation protocol biopsies. These patients received tocilizumab for 6 months posttransplantation. When tocilizumab was stopped, two patients developed mild AMR at 1 year for-cause biopsies. This again suggests the possibility of rebound IL-6-IL-6R signaling that reinvigorates the alloimmune response. All patients have retained their grafts to date.
Data reported here were guided by our previous experience with tocilizumab in desensitization and animal model data (17, 20) . We designed a rescue protocol to 2 compared with our patients and, thus, were unlikely to respond to any therapy. We also believe that there is a "tipping point" where therapeutic interventions would be unlikely to stabilize eGFR. For our adult patients, eGFR of 37.5 mL/min/1.73 m 2 at the time of index biopsy showed eGFR stabilization over 36 months.
The results presented here suggest tocilizumab can alter iDSA production, stabilize allograft function, reduce inflammatory markers of cAMR, and possibly improve patient and graft survival compared with survival rates for cAMR reported in the literature (34, 35) . We also noted that four allograft losses in our tocilizumab-treated patients occurred about 5 months after the termination of tocilizumab therapy. Outcomes for our patients with cAMR and TG who were not treated with tocilizumab are similar to those reported in the literature, with graft survival at 2 years of about 50%. We were also encouraged to see reductions in C4d + staining and g plus ptc scores in nine patients who had pretocilizumab and 1-year posttocilizumab biopsies. C4d + and g plus ptc scores >2 have recently been shown to represent the most prominent features of AMR that are associated with poor long-term outcomes (36) .
In addition, recent data from a nonhuman primate model of lung transplantation suggest that tocilizumab is critical for long-term rejection-free survival. Tocilizumab treatment was associated with an increase in Tregs and inhibition of DSA generation posttransplantation (37) . Of interest in this model is the importance of T cell depletion at transplantation to maximize the induction of Tregs by tocilizumab. This is also similar to the protocol we used posttransplantation in our highly HLA-sensitized patients receiving desensitization with IVIg plus tocilizumab, where we saw rapid reductions of DSAs and no evidence of AMR on protocol biopsies performed at 6 months (20) .
We are aware that the results of this case series are not definitive and need rigorous assessment in a controlled clinical trials setting. However, tocilizumab and other agents that interfere with the IL-6-IL-6R signaling cascade may represent a way forward in the management of what is now considered an untreatable condition of renal allografts resulting in the most prominent cause of allograft failures in the United States. 
